UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

The New England journal of medicine, 2022-11, Vol.387 (20), p.1855-1864

2022

Volltextzugriff (PDF)

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

The American heart journal, 2022-09, Vol.251, p.61-69

2022

Volltextzugriff (PDF)

Effect of Evolocumab on Coronary Plaque Composition

Journal of the American College of Cardiology, 2018-10, Vol.72 (17), p.2012-2021

2018

Volltextzugriff (PDF)

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Journal of the American Heart Association, 2019-02, Vol.8 (4), p.e010932-e010932

2019

Volltextzugriff (PDF)

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies

Circulation Journal, 2017/06/23, Vol.81(7), pp.1029-1035

2017

Volltextzugriff (PDF)

Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study

Journal of the International Neuropsychological Society, 2021-11, Vol.27 (10), p.1048-1057

2021

Volltextzugriff (PDF)

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

Clinical cardiology (Mahwah, N.J.), 2018-10, Vol.41 (10), p.1328-1335

2018

Volltextzugriff (PDF)

SEX-RELATED DIFFERENCE IN THE REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB: INSIGHTS FROM GLAGOV

Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A1077-A1077

2018

Volltextzugriff (PDF)

GREATER LIKELIHOOD OF REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB, IN PATIENTS WITH HIGHER LP(A) LEVELS

Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A17-A17

2018

Volltextzugriff (PDF)

Benefits and limitations of multimodality imaging in the diagnosis of a primary cardiac lymphoma

Texas Heart Institute journal, 2014-12, Vol.41 (6), p.657-659

2014

Volltextzugriff (PDF)

Magnetic resonance imaging of cardiac tumors: experience of a tertiary medical center

Journal of cardiovascular magnetic resonance, 2013-01, Vol.15 (Suppl 1), p.E104-E104, Article E104

2013

Volltextzugriff (PDF)

Erratum to “C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV” [American Journal of Preventive Cardiology 3C (2020) 100091]

American journal of preventive cardiology, 2021-06, Vol.6, p.100153-100153, Article 100153

2021

Volltextzugriff (PDF)

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

American journal of preventive cardiology, 2020-09, Vol.3, p.100091-100091, Article 100091

2020

Volltextzugriff (PDF)

Relationship Between Coronary Atherosclerotic Plaque Burden Measured By Intravascular Ultrasound And Cardiovascular Disease Outcomes

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.681-682

2016

Volltextzugriff (PDF)

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-12, Vol.316 (22), p.2373

2016

Volltextzugriff (PDF)

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment

European heart journal, 2019-09, Vol.40 (33), p.2775-2781

2019

Volltextzugriff (PDF)

Abstract 12103: Intraindividual Variability in Serial Lipoprotein(a) Concentration Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial

Circulation (New York, N.Y.), 2023-11, Vol.148 (Suppl_1)

2023

Volltextzugriff (PDF)

Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation

Circulation (New York, N.Y.), 2019-10, Vol.140 (17), p.1426-1436

2019

Volltextzugriff (PDF)

ASSOCIATION OF BASELINE LIPOPROTEIN(A) AND PERCENTAGE OF LIPOPROTEIN(A) LOWERING WITH OLPASIRAN

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.1130-1130

2023

Volltextzugriff (PDF)

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

JAMA cardiology, 2017-06, Vol.2 (6), p.598

2017

Volltextzugriff (PDF)

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

Cardiovascular diagnosis and therapy, 2021-02, Vol.11 (1), p.120-129

2021

Volltextzugriff (PDF)

EFFECT OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB IN PATIENTS WITH ANGIOGRAPHIC CORONARY ARTERY DISEASE: RESULTS OF THE GLAGOV OPEN LABELLED EXTENSION STUDY

Journal of the American College of Cardiology, 2020-03, Vol.75 (11), p.1869-1869

2020

Volltextzugriff (PDF)

Evolocumab: Considerations for the Management of Hyperlipidemia

Current atherosclerosis reports, 2018-04, Vol.20 (4), p.17-17, Article 17

2018

Volltextzugriff (PDF)

Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a)

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A13951-A13951

2020

Volltextzugriff (PDF)

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

The American heart journal, 2016-06, Vol.176, p.83-92

2016

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Cardiovascular System & Cardiology
(15)
Humans
(15)
Cardiac & Cardiovascular Systems
(14)
Atherosclerosis
(9)
Cardiovascular Disease
(9)
Female
(8)
Middle Aged
(8)
Cardiology
(6)
Cholesterol
(6)
Cholesterol, Ldl - Blood
(6)
Male
(6)
Aged
(5)
Arteriosclerosis
(5)
Clinical Trials
(5)
Double-Blind Method
(5)
Hypercholesterolemia - Drug Therapy
(5)
Monoclonal Antibodies
(5)
Proprotein Convertase 9 - Antagonists & Inhibitors
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

Effect of Evolocumab on Coronary Plaque Composition

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies

Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

SEX-RELATED DIFFERENCE IN THE REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB: INSIGHTS FROM GLAGOV

GREATER LIKELIHOOD OF REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB, IN PATIENTS WITH HIGHER LP(A) LEVELS

Benefits and limitations of multimodality imaging in the diagnosis of a primary cardiac lymphoma

Magnetic resonance imaging of cardiac tumors: experience of a tertiary medical center

Erratum to “C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV” [American Journal of Preventive Cardiology 3C (2020) 100091]

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

Relationship Between Coronary Atherosclerotic Plaque Burden Measured By Intravascular Ultrasound And Cardiovascular Disease Outcomes

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment

Abstract 12103: Intraindividual Variability in Serial Lipoprotein(a) Concentration Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial

Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation

ASSOCIATION OF BASELINE LIPOPROTEIN(A) AND PERCENTAGE OF LIPOPROTEIN(A) LOWERING WITH OLPASIRAN

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

EFFECT OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB IN PATIENTS WITH ANGIOGRAPHIC CORONARY ARTERY DISEASE: RESULTS OF THE GLAGOV OPEN LABELLED EXTENSION STUDY

Evolocumab: Considerations for the Management of Hyperlipidemia

Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a)

Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

Suchergebnisse filtern